Our results presented a promising antitumor effect of anti-PD-1 plus SBRT, suggesting that immunotherapy combined with radiotherapy could be a potentially feasible clinical strategy for early-stage resectable HCC, as evidenced by the numerically higher ORR and high disease control rate observed in our study. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.